<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00209898</url>
  </required_header>
  <id_info>
    <org_study_id>12952</org_study_id>
    <nct_id>NCT00209898</nct_id>
  </id_info>
  <brief_title>Hepatitis C Treatment of Inmates</brief_title>
  <acronym>PEGPRI</acronym>
  <official_title>Hepatitis C Treatment of Inmates. A Randomized, Open-label Study Evaluating the Feasibility, Safety and Efficacy of Treatment With Peginterferon Alfa-2a in Combination With Ribavirin in Inmate Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bergen Prison, Norwegian correctional service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis C infection is a prevalent chronic disease. It is particularly prevalent among
      intravenous drug abusers. Bergen fengsel is a regional prison housing 250 inmates, of which
      as many as 70 are recorded HCV RNA PCR positive annuallly. In this study inmate males and
      females will be randomized to standard screening and initiation procedure, or to a rapid
      initiation procedure in the hospital's infectious diseases outpatient clinic. The study aims
      at studying if rapid inclusion will increase the possibility to conclude treatment while the
      prisoner still is incarcerated, thus improve the chances of reaching a sustained virologic
      response, compared to standard inclusion, where prisoners, as other out patients will wait
      for inclusion for several months.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low inclusion rate
  </why_stopped>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- adherence</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>- Sustained virologic response rates defined as percentage of patients with non-detectable HCV-RNA as measured by Roche AMPLICOR HCV Test, v2.0 (&gt;50 IU/mL).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with non-detectable HCV-RNA at study week 12, 24 and 48 as measured by Roche AMPLICOR HCV Test v2.0 (&lt;50 IU/mL).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- adverse event rate and profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Hemoglobin</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Other laboratory tests</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Medical Outcomes Study 36 Item Short Form health Survey (SF-36)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Rapid standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapid standard of care treatment after screening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ordinary standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fast initiation procedure</intervention_name>
    <arm_group_label>Rapid standard of care</arm_group_label>
    <arm_group_label>Ordinary standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serologic evidence of chronic hepatitis C infection by an anti-HCV test

          -  Serum HCV-RNA quantifiable at &gt; 600 IU/mL or 1000 copies/mL by the Roche AMPLICOR HCV
             MONITOR Test, v2.0

          -  Patients with both normal or elevated serum ALT are eligible

          -  Compensated liver disease (Child-Pugh grade A clinical classification)

          -  Patients with cirrhosis or transition to cirrhosis must have an abdominal
             ultrasonography, CT scan or MRI scan without evidence of hepatocellular carcinoma and
             a serum AFP &lt; 100 ng/mL within 2 months of randomization

          -  Negative urine or blood pregnancy test (for women of childbearing potential)
             documented within the 24 hour period prior to first dose of study drug

          -  All fertile males and females receiving RBV must be using two forms of effective
             contraception during treatment and during the 6 months after treatment ends

        Exclusion Criteria:

          -  Women with ongoing pregnancy or breat feeding

          -  Therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment
             (including supraphysiologic soses of steroids and radiation) &lt; 6 months prior to the
             first dose of study drug

          -  Any investigational drug &lt; 6 weeks prior to the first dose of study drug Positive test
             at screening for anti-HAV IgM Ab, HBsAg, anti-HBsAg, anti-HBc Ab, anti-HIV Ab.

          -  History or evidence of a medical condition associated with chronic liver disease other
             than HCV (e.g. hemochromatosis, autoimmune hepatitis, metabolic liver disease,
             alcoholic liver disease, toxin exposures)

          -  History or evidence of bleeding from esophageal varices or other conditions consistent
             with decompensated liver disease

          -  Neutrophil count &lt; 1500/mm or platelet count &lt; 90,000 cells/mm at screening

          -  Serum creatinine level &gt; 1,5 times the ULN at screening

          -  History of severe psychiatric disease, especially depression. Severe psychiatric
             disease is defined as treatment with an antidepressant medication or neuroleptica at
             therapeutic doses for major depression or psychosis, respectively for at least 3
             months at any previous time, or any history of the following; a suicidal attempt,
             hospitalization for psychiatric disease or a period of disability due to psychiatric
             disease

          -  History of severe seizure disorder or current anticonvulsant disease

          -  History of immunologically mediated disease (e.g. IBD, ITP, LED, AIHA, scleroderma,
             severe psoriasis or RA etc.)

          -  History or other evidence of chronic pulmonary disease associated with functional
             limitation

          -  History of major organ transplantation with an existing functional graft

          -  History of severe cardiac disease (e.g. NYHA Functional Class III or IV, myocardial
             infarction within 6 months of ventricular arrhythmias requiring ongoing treatment,
             unstable angina or other significant CVD)

          -  History or other evidence of severe illness, malignancy or other conditions which
             would make the patient, in the opinion of the investigator, unsuitable for the study

          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)

          -  Evidence of ongoing drug abuse (including excessive alcohol consumption)

          -  Inability or unwillingness to provide informed consent or abide by the requirements of
             the study

          -  Male partners of women who are pregnant

          -  Hemoglobin &lt; 12 g/dL in women or &lt; 13g/dL in men at screening

          -  Any patient with an increased baseline risk for anemia or for whom anemia would be
             medically problematic

          -  Patients with documented or presumed coronary artery disease or cerebrovascular
             disease should not be enrolled if, in the judgement of the investigator, an acuter
             decrease in hemoglobin by up to 4 g/dL would not be well-tolerated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steinar Skrede, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit for infectious diseases, Dept. Internal Medicine, Haukeland UH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit for infectious diseases outpatient clincic, Dept. Internal Medicine</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>-Dalgard,O., Jeansson, S., Skaug, K, Raknerud, N., Bell, H. Hepatitis C in the general adult population of Oslo; prevalence and clinical spectrum. Scand. J. Gastroenterol. 38:864-870, 2003. -Stein, M.D., Maksad, J., Clarke, J. Hepatitis C among injecting drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alc. Depend. 61:211-215, 2001. -Allen,S.A., Spaulding,A.C., Osei,A.M., Taylor,L.E., Cabral,A.M. and Rich,J.D. Treatment of chronic hepatitis C in a state correctional facility. Ann. Intern. Med. 138:187-190, 2003. -Dalgard,O., Bj√∏ro,K., Hellum,K., Skaug,K., Gutigard,B.,Bell, H. Treatment of chronic hepatitis C in injecting drug users: 5 years' folow up. Eur. Addict. Res. 8:45-49, 2002.</citation>
  </reference>
  <verification_date>June 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Haukeland University Hospital</investigator_affiliation>
    <investigator_full_name>Steinar Skrede</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Chronic hepatits C</keyword>
  <keyword>peginterferon</keyword>
  <keyword>ribavirin</keyword>
  <keyword>inmate</keyword>
  <keyword>fast initiation procedure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

